Palonosetron Hydrochloride Qilu Pharma Spain

Palonosetron, the active ingredient in Palonosetron Hydrochloride Qilu Pharma Spain, is a 5-HT3 receptor antagonist presented as a sterile injectable solution for intravenous use. It is employed to prevent chemotherapy‑induced nausea and vomiting in adult cancer patients. GNH USA supplies Palonosetron Hydrochloride Qilu Pharma Spain as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Palonosetron is a selective 5‑HT3 receptor antagonist used in the management of nausea and vomiting associated with chemotherapy and surgery. - Chemotherapy‑induced nausea and vomiting (CINV): Provides long‑lasting protection against acute and delayed episodes. - Post‑operative nausea and vomiting (PONV): Reduces the incidence of nausea and vomiting after general anesthesia. - Radiotherapy‑induced nausea and vomiting: Helps mitigate the nausea associated with certain radiation treatments.

Palonosetron is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache - Constipation - Fatigue - Diarrhoea - Dizziness - Injection site erythema

Serious or Rare Side Effects: - Severe hypersensitivity reactions (anaphylaxis, angio‑oedema) - Prolonged QT interval on ECG  - Serotonin syndrome (when combined with other serotonergic agents) - Cardiac arrhythmia - Severe local tissue injury at the injection site

Palonosetron should be used with careful clinical assessment. - Cardiac monitoring: Patients with known QT‑prolongation or electrolyte  t  t  t  ...  ... ... ....  ... ... ... ... … … ... … …  … … … … … ... ... … …  …  … … ... ... ... ... … … … … … … … … … … … … … … … ... … … … … … … … … … ... … ……………………………………………………… … … … … … … … … … … … … … … … …  - Concomitant drug   g   t   t  d  d  ewline  ewline  ewline  ewline  ewline  ewline  ewline  ewline ullet  ewline  ewline  ewline  ewline  ewline ullet  ewline ... ... ... ... ... ... ... ... ... ... ... ... ...